Japan's Leading Crypto Tax Platform, cryptact, Launches in India
cryptact, Japan's most trusted crypto tax platform with over 150,000 users since 2017, is now officially available in India. Developed by former Goldman Sachs executives, cryptact combines institutional-grade expertise with cutting-edge technology to simplify crypto tax filing with accuracy, transparency, and ease. Indian users can now access its powerful tax tool completely free of charge.
Business Wire India
cryptact, Japan's most trusted crypto tax platform with over 150,000 users since 2017, is now officially available in India. Developed by former Goldman Sachs executives, cryptact combines institutional-grade expertise with cutting-edge technology to simplify crypto tax filing with accuracy, transparency, and ease. Indian users can now access its powerful tax tool completely free of charge.
pafin Inc. (Co-CEOs Amin Azmoudeh and Gaku Saito), the provider of cryptact, today announced the platform's launch in India. cryptact is a leading cryptocurrency tax calculation solution designed to help users manage the complexities of crypto taxation through a simple and reliable interface.
Founded by former Goldman Sachs executives with deep backgrounds in global finance and technology, cryptact offers users a seamless experience in calculating profits, losses, and income from a wide range of crypto activities—including trading, DeFi, and NFTs.
To mark this launch, cryptact is offering free, full-feature access to all users in India, with no subscription or payment required.
This expansion makes India the third country where cryptact is officially available, following its successful rollouts in Japan and Canada. It reflects pafin's ongoing mission to support crypto investors around the world with trusted, easy-to-use tax tools.
Key Features of cryptact Japan's leading crypto tax service: since 2017, cryptact has served over 150,000 users in Japan. Built by a multicultural team in Tokyo with expertise in finance, technology, and blockchain, it is widely recognized for its reliability and accuracy.
Extensive asset and exchange coverage : cryptact supports over 24,000 cryptocurrencies across 137 exchanges and blockchains, offering one of the most comprehensive coverage levels in the industry.
Full-featured free access for Indian users: cryptact is now available in India completely free of charge. Indian users can access all core features—including tax calculations for capital gains, DeFi, and NFT transactions—with support for up to 10,000 transactions per year under our India Exclusive Plan. This plan is specially designed to meet the growing needs of Indian crypto investors and is available at no cost.
Support for all past tax years: users can calculate tax obligations for any year—not just the current tax year—making it ideal for both first-time filers and those catching up on previous filings.
Accurate and reliable calculations: cryptact applies locally researched tax logic tailored to India's regulations, ensuring accuracy and compliance even in the absence of formal tax authority guidance.
Automatic identification of DeFi and NFT transaction types: by simply entering a wallet address, users can automatically import transaction histories and identify transaction types—eliminating much of the manual work involved in crypto tax preparation.
Get Started with cryptact in India
Sign up and begin using cryptact's full suite of features for free—no credit card required.
https://www.cryptact.com/en
Future Outlook
'We are excited to support cryptocurrency users in India and help them manage their tax reporting with greater ease and accuracy. Going forward, we will continue expanding support for additional cryptocurrencies, exchanges, and blockchains to enhance the experience for Indian users,' said Amin Azmoudeh, Co-CEO, pafin Inc.
Leadership Profiles
Amin Azmoudeh, Co-CEO
After graduating with a BS in Computer Science and a BA in Japanese from the University of Maryland in 2003, Amin joined Goldman Sachs Tokyo as the sole technologist of Tokyo's GSPS team, a principal strategies unit managing the firm's capital. In 2005, he changed careers to become a financial analyst with GSPS, and in 2007, he transferred to GSIP (Goldman Sachs Investment Partners) as part of the spin-out of the team into GSAM. As a financial/analyst and portfolio manager, Amin managed listed/unlisted equities, bonds, swaps, interest rate products, foreign exchange, derivatives as well as overall risk management. He was promoted to Managing Director in 2013 and retired from Goldman Sachs on December 31, 2017, to found cryptact.
Gaku Saito, Co-CEO
Having completed a Bachelor's degree in System Innovation Engineering in 2005 and a Master's degree in Environmental & Ocean Engineering in 2007 from The University of Tokyo, Gaku joined Goldman Sachs – Asia Special Situations Group, where he executed investments exceeding US$500 million in non-performing and sub-performing loan portfolios, private equity, real estate portfolios, and vessel portfolios. Also, he participated in a number of sponsorship auctions on bankrupt real estate developers. From May 2010 to January 2019, he worked at Goldman Sachs Investment Partners as a portfolio manager at a multiasset hedge fund, managing an US$800 million portfolio. His main investment strategy was equity long/short in listed companies based on a fundamental approach to building financial models. He also invested in equity derivatives, bond/CDS, FX, and mezzanine loan products. Since February 2019, he has been serving as Co-CEO of cryptact, and in 2021, he was appointed as Chairman of the JCBA Tax Review Department.
About the Team
cryptact is developed and operated by a diverse, multinational team. With expertise in finance, technology and blockchain, the team brings a global perspective to deliver a trusted and efficient crypto tax service.
https://www.pafin.com/en#team
Disclaimer: The above press release comes to you under an arrangement with Business Wire India. Business Upturn take no editorial responsibility for the same.
Ahmedabad Plane Crash
Business Wire India, established in 2002, India's premier media distribution company ensures guaranteed media coverage through its network of 30+ cities and top news agencies.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
28 minutes ago
- Yahoo
Kontoor Brands, Inc. (KTB): 'People Want, Ooh, Hally Hansen,' Says Jim Cramer
We recently published . Kontoor Brands, Inc. (NASDAQ:KTB) is one of the stocks Jim Cramer recently discussed. Kontoor Brands, Inc. (NASDAQ:KTB)'s shares, like its peers in the retail and apparel industry, haven't performed well in 2025 as they are down by 15% year-to-date. The firm has struggled from weak consumer sentiment that led to a disappointing full year guidance in February and dealt a massive blow to the stock. However, Kontoor Brands, Inc. (NASDAQ:KTB) has benefited recently from its acquisition of retailer Helly Hansen, which has a strong presence in Vietnam. Cramer commented on the deal: 'Just watch this. Kontoor Brands. This morning, Goldman puts it on its Conviction List. Why? Because of Helly. . .well Helly Hansen is a brand that is so huge in Canada they bought it the deal has just closed. I think they're going to blow out Helly Hansen, which makes the best outdoor clothes I have ever had. We used it exclusively in British Columbia. And, now that stock is going to go up five. Because people want, ooh, Hally Hansen, Goldman Sachs recommended, I know HH, that's a good brand. I think that's a good idea. I'm going to go buy it. Because that's what happening. Not basis points!' A view of a designer staff in front of a studio with lifestyle apparel they designed. Cramer discussed the acquisition and the earnings in March: 'I got blown up there, I had them on to introduce the HH purchase. And it seemed really great and I got blown up, because I had the, they had preannounced the numbers but they didn't talk the forecast so I apologize to anyone who watched the report. Because I didn't know that the forecast was bad. And the forecast is, I always tell David, is the forecast.' While we acknowledge the potential of KTB as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity
Wall Street's smartest money has quietly amassed over $150 million in bullish positions, with Goldman Sachs eliminating all downside hedges. Despite trading near 52-week lows due to biotech industry headwinds, Viking's oral GLP-1 drug shows unprecedented tolerability that could revolutionize obesity treatment. Upcoming phase 2 oral data expected in October or November 2025 represents a rare binary event where the market significantly undervalues the upside potential. 10 stocks we like better than Viking Therapeutics › Most investors have written off biotech stocks as a graveyard of broken dreams. While artificial intelligence (AI) captures Wall Street's imagination, the biotech industry -- once the crown jewel of innovation -- has been left for dead. But beneath the wreckage, Wall Street's sharpest funds are quietly positioning for what could be the most significant metabolic breakthrough in a generation. Viking Therapeutics (NASDAQ: VKTX) is developing VK2735, a dual GLP-1/GIP receptor agonist for obesity treatment. The company reported stellar phase 2 results in February 2024, showing 14.7% weight loss at 13 weeks with the injectable formulation. But here's what makes Viking different: Its drug demonstrated unprecedented tolerability with a 13% discontinuation rate that was no higher than placebo -- a stark contrast to competing GLP-1 drugs. In obesity treatment, tolerability isn't a luxury -- it's key to real-world adoption. Viking's breakthrough with VK2735 isn't just efficacy; it's safety. The drug's 13% discontinuation rate matched placebo -- unlike Wegovy and Zepbound, which see discontinuation rates typically five to 10 percentage points higher than their placebo groups. Tolerability indistinguishable from placebo could expand the entire obesity market -- not just capture share. The obesity drug market is projected to reach $200 billion by 2030, yet current treatments face significant limitations. Novo Nordisk's Wegovy and Eli Lilly's Zepbound require weekly injections and cause severe gastrointestinal side effects in many patients. Viking's oral formulation, currently in phase 2 trials with data expected in the October-to-November time frame, could be the first pill to roughly match injectable efficacy without the tolerability issues. Here's what Wall Street might be missing: Viking's superior tolerability profile doesn't just mean competing for market share -- it could lift the roof on the entire obesity category. With no greater discontinuation than placebo, VK2735 could dramatically expand the addressable market by reaching patients who currently avoid or quit treatment due to side effects. An effective, well-tolerated oral option could double or triple the number of patients seeking treatment. The numbers tell a compelling story: Viking showed a near-perfect dose-response relationship, with tolerability no different than placebo -- something no other GLP-1 developer has achieved. Every major pharma has tried and failed to create an effective oral GLP-1, with Pfizer discontinuing its program due to safety issues and an exceptionally high discontinuation rate (> 50%). Viking appears to have cracked the code based on the early data, and Wall Street seems to know it (more on that later). Viking's stock has plummeted 64% from its 52-week high of $81.73 to around $27 as of July 2. This devastation reflects broader structural damage in the biotech space rather than company-specific issues. Since interest rates have flipped higher, biotech as a whole has been crushed, leaving a bad taste in investors' mouths. The 2022 biotech collapse has created a vicious cycle. Great opportunities are no longer getting flagged for investors, as AI stocks dominate headlines and capture imaginations. Meanwhile, GLP-1 drugs have shown a mixed bag in clinical trials lately, suggesting to some that a top in efficacy and safety is near. But I believe that's shortsighted thinking. VK2735 has shown a differentiated clinical profile, with tolerability nearly indistinguishable from placebo in early studies -- something no other GLP-1 has achieved. While it's far too early to declare victory, the data suggests Viking may have solved one of the key challenges that has plagued obesity drugs. This widespread biotech pessimism has created the kind of mispricing sophisticated funds live for: quality assets trading at distressed valuations. It's the very definition of an asymmetric opportunity. While retail investors panic, institutional behavior reveals extreme confidence. Per the latest 13F filings, Balyasny Asset Management holds $71 million in bullish positions, up 542% from the previous quarter. Citadel owns $32 million, Susquehanna has $36 million, and Jane Street holds $17.5 million. Combined, these sophisticated quantitative funds have accumulated over $150 million in bullish positions. More telling is what Goldman Sachs just did: It eliminated 100% of its put positions while increasing calls by 350%. When one of Wall Street's premier trading desks removes all downside protection, it's signaling extreme confidence in the outcome. These institutions aren't speculating randomly -- they're arbitraging what they see as a massive market inefficiency. Their models likely show the same disconnect: a drug with tolerability on par with placebo, and a validated mechanism trading as if it has a 96.5% chance of complete failure. For quant funds that live and die by probabilities, this represents a rare mispricing opportunity. The divergence between institutional longs and retail shorts has reached an extreme. Short interest just increased to 30% of float as of June 13, up from 26% the prior month -- even as the smart money accumulates massive call positions. For context, 30% short interest is extraordinarily high for a clinical-stage biotech, putting Viking in the 99th percentile of U.S. equities for bearish bets. This sets the stage for a classic capitulation moment, where good news could ignite both fundamental revaluation and a violent short squeeze. Manufacturing is the Achilles' heel of most small-cap biotechs. Viking solved this early. In March 2025, the company inked a $150 million manufacturing deal with CordenPharma -- one of the world's premier peptide contract development and manufacturing organizations (CDMOs) -- giving Viking turnkey capacity for 100 million autoinjectors and 1 billion tablets annually, without dilution or costly infrastructure builds. This agreement removes a major overhang that has plagued other clinical-stage biotechs, as well as serves as a clear green flag that the broader market has curiously decided to ignore. After all, such an agreement would not have been signed without deep due diligence and extreme confidence in VK2735's clinical profile. Why? There is a tsunami of demand for GLP-1 manufacturing capacity right now. The phase 2 oral data release expected in the fourth quarter of 2025 represents a rare asymmetric opportunity. Based on the dose-response curves from the four-week data showing 6.8% weight loss, the oral formulation could potentially approach injectable-like efficacy. The full 13-week phase 2 data will reveal how close the oral formulation can get to the 14.7% weight loss seen with the injectable. At today's $3 billion market cap, Viking trades at a fraction of the value created by successful GLP-1 drugs. Eli Lilly has added over $300 billion in market value since Mounjaro's 2022 launch, while Novo Nordisk saw its valuation surge from under $200 billion to over $600 billion at its peak as Ozempic and Wegovy transformed the obesity market. Even with recent pullbacks, both companies have captured hundreds of billions in incremental value from their GLP-1 franchises alone. The market's high bar for new entrants was evident when Amgen's MariTide showed 20% weight loss but disappointed with 11% discontinuation rates in its phase 2 trial. When the data was released in November 2024, shares fell nearly 5% that day despite the solid efficacy. Yet Viking's parity with placebo appears to clear that bar with room to spare. If Viking's oral drug approaches the injectable's efficacy, the stock could see immediate revaluation to $200 to $300 per share, with longer-term potential exceeding $500. At current levels, the market is implying just a 3.5% probability of success for VK2735. That's absurd when you consider that metabolic drugs with positive phase 2 data typically have 45% to 50% success rates through approval. With VK2735's validated mechanism and placebo-like tolerability, a reasonable probability may range from 45% to 70% -- significantly above the market's implied odds. Even using just a 25% success rate -- below the industry average -- suggests the stock should trade above $100 right now. At $27, the market is pricing Viking as a lottery ticket. The data says it's closer to loaded dice. The risk-reward setup has convinced me to take a leveraged position through deep out-of-the-money call options -- admittedly a speculative position that could expire worthless. But with Viking having about $7.50 per share in cash, even equity investors have defined downside risk in a worst-case scenario. Add in 30% short interest providing squeeze fuel and institutional positioning at extreme levels, and the asymmetric opportunity becomes clear. Key risks include potential safety issues emerging in larger trials, manufacturing scale-up challenges despite CordenPharma's support, and commercial headwinds such as payer reluctance to cover costly new obesity treatments. But the statistical improbability of VK2735's tolerability profile, combined with the manufacturing validation and institutional positioning, suggests the smart money sees something the broader market is missing. My personal take on the maximum upside? If VK2735 secures oral GLP-1 leadership and achieves widespread commercial adoption, a strategic acquisition could command valuations approaching $750 per share within the decade -- though this remains a highly speculative scenario contingent on flawless execution. A lot has to happen between now and then to make this come to fruition. But the seed has been planted. VK2735 has a real shot at bending the curve on the obesity epidemic. Markets move in cycles. "Returning is the motion of the Tao," as Lao Tzu wrote -- when one extreme is reached, movement toward the opposite begins. Biotech will rise again. Viking offers investors a chance to front-run that rotation -- not by chasing speculative names, but by owning a promising asset with game-changing potential at what may prove to be generational lows. As biotech's cycle inevitably turns, those positioned early in assets like Viking may capture the steepest part of the revaluation curve. Before you buy stock in Viking Therapeutics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Viking Therapeutics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $692,914!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $963,866!* Now, it's worth noting Stock Advisor's total average return is 1,049% — a market-crushing outperformance compared to 179% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 30, 2025 George Budwell has positions in Pfizer and Viking Therapeutics and has the following options: long January 2026 $55 calls on Viking Therapeutics, long January 2026 $60 calls on Viking Therapeutics, and long January 2027 $60 calls on Viking Therapeutics. The Motley Fool has positions in and recommends Amgen, Goldman Sachs Group, and Pfizer. The Motley Fool recommends Novo Nordisk and Viking Therapeutics. The Motley Fool has a disclosure policy. Why I Think Viking Therapeutics Is an Asymmetric Growth Opportunity was originally published by The Motley Fool Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
Goldman Sachs Rates Johnson & Johnson a Buy, Citing Pipeline Strength and Policy Tailwinds
Johnson & Johnson (NYSE:JNJ) ranks among the best set-it-and-forget-it stocks to buy. Asad Haider, a Goldman Sachs analyst, remained optimistic about Johnson & Johnson (NYSE:JNJ) shares, rating it as a Buy on June 5. The analyst noted several factors that lead to the update. Pixabay/Public Domain Similar to its industry peers, the company demonstrates a proactive approach to navigating regulatory environments by participating in policy discussions with the administration. This could result in positive outcomes in areas such as 340B reform and PBM. Johnson & Johnson's innovation skills are further demonstrated by the company's pharmaceutical pipeline achievements, including the encouraging Carvykti data and the expected approval of TAR-200. The company's strategic move from Stelara to Tremfya and its investments in commercial fulfillment further highlight its commitment to preserving a dominant market position. Johnson & Johnson (NYSE:JNJ) is a notable name in the healthcare industry, which includes sub-sectors like pharmaceuticals, medical equipment, and consumer health products. The company is known for creating medications to treat a variety of conditions and diseases, including cancer, diabetes, and HIV/AIDS. While we acknowledge the potential of JNJ as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. Read More: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
